The combined action of broncholytic agents in asthmatic patients: orciprenaline, isoprenaline, and ephedrine.
D000336:Aerosols; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D004809:Ephedrine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use*; D008297:Male; D009921:Metaproterenol / Q000627:therapeutic use; D010627:Phenethylamines / Q000627:therapeutic use*; D012118:Resorcinols / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D012138:Respiratory Therapy
D000336:Aerosols; D001993:Bronchodilator Agents; D010627:Phenethylamines; D012118:Resorcinols; D009921:Metaproterenol; D004809:Ephedrine; D007545:Isoproterenol